Charles River Laboratories (NYSE: CRL) insider transactions
In the twelve months to 10 November 2026, executives and directors of Charles River Laboratories reported 21 open-market sales of 193,169 shares ($52.1m) and 2 open-market purchases of 35 shares ($7,338), by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 November 2026 | Knell Michael Gunnar | SVP, Finance and CAO | Shares withheld for tax | −649 | $313.02 | 11,203 | Form 4 |
| 22 October 2026 | Foster James C | Director | Option exercise, 10b5-1 plan | +24,042 | $244.41 | 55,638 | Form 4 |
| 22 October 2026 | Foster James C | Director | Open-market sale, 10b5-1 plan | −24,042 | $350.00 | 31,596 | Form 4 |
| 21 October 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Option exercise, 10b5-1 plan | +2,156 | $244.41 | 6,963 | Form 4 |
| 21 October 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Open-market sale, 10b5-1 plan | −2,156 | $344.41 | 4,807 | Form 4 |
| 5 October 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Option exercise, 10b5-1 plan | +981 | $208.44 | 5,788 | Form 4 |
| 5 October 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Open-market sale, 10b5-1 plan | −981 | $308.44 | 4,807 | Form 4 |
| 30 September 2026 | Coleman Glenn | EVP & Chief Financial Officer | Open-market purchase | +10 | $297.43 | 27,762 | Form 4 |
| 25 August 2026 | Foster James C | Director | Option exercise, 10b5-1 plan | +21,132 | $194.12 | 52,728 | Form 4 |
| 25 August 2026 | Foster James C | Director | Option exercise, 10b5-1 plan | +12,429 | $208.44 | 65,157 | Form 4 |
| 25 August 2026 | Foster James C | Director | Open-market sale, 10b5-1 plan | −33,561 | $300.00 | 31,596 | Form 4 |
| 19 August 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Option exercise, 10b5-1 plan | +2,039 | $194.12 | 6,846 | Form 4 |
| 19 August 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Open-market sale, 10b5-1 plan | −2,039 | $294.12 | 4,807 | Form 4 |
| 19 August 2026 | Girshick Birgit | Chief Executive Officer | Gift | −528 | — | 35,485 | Form 4 |
| 18 August 2026 | Andrews Nancy C | Director | Option exercise | +573 | $164.30 | 2,011 | Form 4 |
| 18 August 2026 | Andrews Nancy C | Director | Open-market sale | −573 | $285.24 | 1,438 | Form 4 |
| 11 August 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Option exercise, 10b5-1 plan | +3,714 | $179.66 | 8,521 | Form 4 |
| 11 August 2026 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | Open-market sale, 10b5-1 plan | −3,714 | $279.66 | 4,807 | Form 4 |
| 11 August 2026 | Girshick Birgit | Chief Executive Officer | Option exercise, 10b5-1 plan | +6,500 | $179.66 | 42,513 | Form 4 |
| 11 August 2026 | Girshick Birgit | Chief Executive Officer | Open-market sale, 10b5-1 plan | −6,500 | $279.90 | 36,013 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Charles River Laboratories page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.